516 related articles for article (PubMed ID: 17826966)
1. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
[TBL] [Abstract][Full Text] [Related]
2. Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement.
Vadia N; Rajput S
Eur J Pharm Sci; 2012 Jan; 45(1-2):8-18. PubMed ID: 22067974
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
4. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
Zahedi P; Lee PI
Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
[TBL] [Abstract][Full Text] [Related]
5. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
6. Mesoporous silica material TUD-1 as a drug delivery system.
Heikkilä T; Salonen J; Tuura J; Hamdy MS; Mul G; Kumar N; Salmi T; Murzin DY; Laitinen L; Kaukonen AM; Hirvonen J; Lehto VP
Int J Pharm; 2007 Feb; 331(1):133-8. PubMed ID: 17046183
[TBL] [Abstract][Full Text] [Related]
7. Use of SBA-15 for furosemide oral delivery enhancement.
Ambrogi V; Perioli L; Pagano C; Marmottini F; Ricci M; Sagnella A; Rossi C
Eur J Pharm Sci; 2012 May; 46(1-2):43-8. PubMed ID: 22365882
[TBL] [Abstract][Full Text] [Related]
8. Influence of cyclodextrin complexation on piroxicam gel formulations.
Jug M; Bećirević-Laćan M; Kwokal A; Cetina-Cizmek B
Acta Pharm; 2005 Sep; 55(3):223-36. PubMed ID: 16375834
[TBL] [Abstract][Full Text] [Related]
9. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
10. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
11. Econazole nitrate-loaded MCM-41 for an antifungal topical powder formulation.
Ambrogi V; Perioli L; Pagano C; Marmottini F; Moretti M; Mizzi F; Rossi C
J Pharm Sci; 2010 Nov; 99(11):4738-45. PubMed ID: 20845470
[TBL] [Abstract][Full Text] [Related]
12. Studies on aging piroxicam-polyvinylpyrrolidone solid dispersions.
Ingkatawornwong S; Kaewnopparat N; Tantishaiyakul V
Pharmazie; 2001 Mar; 56(3):227-30. PubMed ID: 11265589
[TBL] [Abstract][Full Text] [Related]
13. Fast dissolving cyclodextrin complex of piroxicam in solid dispersion part I: influence of β-CD and HPβ-CD on the dissolution rate of piroxicam.
Bouchal F; Skiba M; Chaffai N; Hallouard F; Fatmi S; Lahiani-Skiba M
Int J Pharm; 2015 Jan; 478(2):625-32. PubMed ID: 25522828
[TBL] [Abstract][Full Text] [Related]
14. Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-beta-cyclodextrin inclusion complex.
Jug M; Bećirević-Laćan M; Cetina-Cizmek B; Horvat M
Pharmazie; 2004 Sep; 59(9):686-91. PubMed ID: 15497750
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and enhancement of physical stability of semi-solid dispersions containing piroxicam into hard gelatin capsules.
Karataş A; Bekmezci S
Acta Pol Pharm; 2013; 70(5):883-97. PubMed ID: 24147368
[TBL] [Abstract][Full Text] [Related]
16. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
17. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
[TBL] [Abstract][Full Text] [Related]
18. Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol.
Karataş A; Yüksel N; Baykara T
Farmaco; 2005 Sep; 60(9):777-82. PubMed ID: 16084514
[TBL] [Abstract][Full Text] [Related]
19. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
[TBL] [Abstract][Full Text] [Related]
20. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
